clinical trial · NCT05873686
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal CancerMesotheliomaNon-Small Cell Squamous Lung CancerNon-small Cell Lung AdenocarcinomaNXP900
brief summary
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
started
Oct 26, 2023
primary completion
Mar 1, 2027
completion
Jul 1, 2027
last updated
Mar 3, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol